At a glance
- Originator Aventis
- Developer Procter & Gamble
- Class Antiulcers
- Mechanism of Action Cholecystokinin B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Peptic ulcer
Most Recent Events
- 16 Jul 1998 No-Development-Reported for Peptic ulcer in USA (Unknown route)
- 13 Sep 1995 Preclinical development for Peptic ulcer in USA (Unknown route)